back to explore

BRVE

Braveheart Bio, Inc.

NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2026-08-06

$21.39

+0.35 (+1.66%)

last quote

Want the full multi-source brief on BRVE?

The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.

Today

Open

$21.39

High

$21.53

Low

$20.24

Previous close

$21.04

Fundamentals

Market cap

$1.89B

P/E (TTM)

—

P/S (TTM)

—

P/B

—

Gross margin

—

Operating margin

—

Net margin

—

Rev growth (YoY)

—

EPS growth (YoY)

—

ROE

—

52W high

$32.00

52W low

$17.86

Beta

-5.06x

Industry peers

by market cap

TRLV+3.96%HRMY-2.35%SEPN+1.16%TRVI+1.69%XERS+1.77%MAZE+6.19%ANIP+2.28%NUVB+2.18%

Recent SEC filings

CIK 2131524filing-language history →

SCHEDULE 13D/A2026-09-10

10-Q2026-09-08reports 2026-06-30

SCHEDULE 13D2026-08-18

32026-08-14reports 2026-08-07

SCHEDULE 13D2026-08-14

Recent news

2026-10-28 → 2026-11-04

The U.S. Stocks Quietly Winning the Chinese Drug Boom

Many of the hot new drug candidates in the U.S. were developed by Chinese companies.

Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature

Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced two upcoming presentations, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM, at the A

Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar

Oral Abstract PresentationTitle: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and

SEC EDGAR Yahoo Finance TradingView Company website

This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial